Brief: Abbott's Next-Generation Amulet 360™ Device Receives CE Mark To Treat People With Atrial Fibrillation At Risk Of Stroke
27/08/2026 14:22
BRIEF-Abbott's Next-Generation Amulet 360™ Device Receives CE Mark To Treat People With Atrial Fibrillation At Risk Of Stroke Aug 27 (Reuters) - Abbott Laboratories ABT.N:
ABBOTT'S NEXT-GENERATION AMULET 360™ DEVICE RECEIVES CE MARK TO TREAT PEOPLE WITH ATRIAL FIBRILLATION AT RISK OF STROKE
ABBOTT - TO EXPAND AMULET 360 USE ACROSS EUROPE IN COMING WEEKS
ABBOTT - FIRST EUROPEAN CASES USING AMULET 360 COMPLETED IN GERMANY AND DENMARK
Source text: ID:nPn6v5Dlra
Further company coverage: ABT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbott Laboratories
See all newsBrief: Abbott Announces Availability Of Panbio Covid-19/Flu A&B Self-Test In Canada
Perrigo to sell infant formula business to MeridianMade for up to $175 million
Brief: Abbott Initiates Pivotal Trial For Cephea™ Device, An Innovative Treatment For Mitral Heart Valve Disease
Corrected: German startup NVision shows new path to quantum computing chips in Nature paper
Brief: Abbott Receives FDA Approval For First Device To Treat Leaks After Heart Valve Replacement